BC Extra | May 8, 2019
Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

Moderna debuts candidate for rare glycogen storage disease  Moderna Inc. (NASDAQ:MRNA) revealed a new preclinical mRNA candidate to treat glycogen storage disease type Ia -- mRNA-3745, which encodes G6PC. The company presented data at the...
BC Innovations | Jan 8, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest the MRGPRX2 activator mastoparan could help treat Staphylococcus aureus skin infection. In cell-based gene reporter assays, the wasp venom toxin mastoparan activated MRGPRX2-mediated phosphorylation of PLC1, which...
BC Innovations | Oct 24, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Cell models A biobank of insertional mutagenesis-derived haploid mouse ESCs could be used to link genes to disease-related phenotypes in homogeneous cell populations. The biobank consists of over 100,000 haploid mouse ESCs with genetically...
BC Extra | Sep 28, 2017
Preclinical News

Researchers report first Haplobank data

In a paper published in Nature , researchers at the Austrian Academy of Sciences and colleagues reported the first data from Haplobank, an open-access haploid mouse embryonic stem cell (ESC) bank created in collaboration with the...
BC Innovations | Mar 21, 2017
Distillery Therapeutics


INDICATION: Ichthyosis Cell culture studies suggest acylceramide or agents that promote its biosynthesis could help treat ichthyosis caused by PNPLA1 mutations. In a HEK cell-based activity assay, expression of disease-associated PNPLA1 mutants decreased PNPLA1 activity...
BC Innovations | Jan 18, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and mouse studies suggest inhibiting PLA2G16 could help treat picornaviral infections. In HeLa cells infected with coxsackievirus, enterovirus, human rhinovirus or other picornaviruses, PLA2G16 knockout decreased infectivity by picornaviruses compared...
BC Innovations | Mar 10, 2016
Distillery Therapeutics

Therapeutics: Lipoprotein-associated phospholipase A2 (PLA2G7; PAFAH; Lp-PLA2)

Ophthalmic disease INDICATION: Diabetic macular edema (DME) In vitro and rat studies identified a PLA2G7 inhibitor that could help treat DME. Chemical synthesis and in vitro studies of pyrimidone analogs identified a compound that inhibited...
BC Innovations | Mar 3, 2016
Emerging Company Profile

SNP it all together

Genomewide association studies can link SNPs to specific disease phenotypes, but the narrow scope of individual SNP studies limits their power of prediction for targeting the associated genes. Genomics plc is developing a computational platform...
BC Innovations | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Phospholipase A2 (PLA2)

Hepatic disease INDICATION: Liver fibrosis; liver disease Mouse studies identified a PLA2 inhibitor that could help treat liver fibrosis and non-alcoholic fatty liver disease (NAFLD). In a mouse model of chemical-induced liver damage, a small...
BC Innovations | Oct 29, 2015
Distillery Therapeutics

Therapeutics: Phospholipase A2 group IID (PLA2G2D)

Infectious disease INDICATION: Respiratory infection; viral infection; SARS-associated coronavirus In vitro and mouse studies suggest inhibiting PLA2G2D in the lungs could help treat viral respiratory infections in elderly patients. Lung levels of the pro-resolving, anti-inflammatory...
Items per page:
1 - 10 of 256